RESEARCH USE ONLY. FOR INFORMATIONAL AND EDUCATIONAL PURPOSES. NOTHING IN THIS ARTICLE CONSTITUTES MEDICAL ADVICE.
TL;DR
The peptide conversation online is dominated by a handful of names: BPC-157, TB-500, GLP-1 agonists, and GH secretagogues. Underneath that noise, five compounds are advancing the actual science in ways worth tracking: LEAP2 (an endogenous “off switch” for the ghrelin receptor, with real human proof-of-concept data), elamipretide/SS-31 (a mitochondria-targeted peptide that became the first FDA-accelerated-approval treatment for Barth syndrome in September 2025), KP1 (a Klotho-fragment peptide that blocks TGF-β signaling and reverses fibrosis in kidney and liver injury models), 4L2-P13D (a lab-discovered macrocyclic peptide that antagonizes IL-11, a cytokine now implicated across kidney, heart, liver, and lung fibrosis), and D13/D41 (AI-designed GLP-1 leads built by screening 10,000 computationally generated sequences down to two candidates with roughly 2.4–2.8× semaglutide’s half-life). None of the five have an established human dosing protocol, and only one (SS-31) is available as a standard research-vial product from mainstream RUO vendors.
What connects them is mechanistic precision: each targets a specific, previously hard-to-drug node (a receptor’s constitutive activity, a mitochondrial membrane phospholipid, a longevity-protein fragment, a fibrotic cytokine, or a computationally optimized binding pocket), rather than a broad, poorly characterized effect.
The Peptide World Is Moving Past Recovery and GH Secretagogues
Asked to name a “research peptide”, most people cite the same five or six names back: BPC-157, TB-500, CJC-1295, Ipamorelin, maybe semaglutide or tirzepatide. That’s not a coincidence: those compounds have large, established literatures and (for the GLP-1 class) genuine approved drugs behind them. But it means the peptide conversation online has calcified around a small, familiar set of targets: growth hormone pulsing, tissue repair, and incretin signaling.
Meanwhile, the actual peptide therapeutics pipeline has kept moving. Endogenous regulatory peptides are being characterized as drug candidates in their own right. A decades-old “longevity protein” is being broken into functional fragments. A cytokine almost nobody outside fibrosis research had heard of five years ago is now a leading drug target. And peptide design itself is changing: from iterative synthesis-and-test cycles to AI systems that generate thousands of candidate sequences before a single one reaches a bench.
The five compounds below aren’t a buying guide. Two have no established synthesis route outside a research lab; two more exist only as published sequences in a journal supplement. What they share is a strong “why researchers should care” narrative: each one illustrates where a specific area of peptide science is actually headed.
1. LEAP2: The Ghrelin “Off Switch”
What it is
LEAP2 (Liver-Expressed Antimicrobial Peptide 2) is an endogenous human peptide, not a synthetic drug candidate. It is produced mainly by the liver and small intestine.
What it’s being researched for
Appetite regulation, obesity, post-meal glucose control, and the broader ghrelin signaling axis.
Why it matters
Ghrelin gets called “the hunger hormone,” and its receptor, GHSR1a, has an unusual property: it stays partially active even with no ghrelin bound at all (constitutive activity). LEAP2 works against both halves of that: it competes with ghrelin for the receptor, and it acts as an inverse agonist that suppresses the receptor’s baseline activity. That’s mechanistically distinct from every major obesity peptide on the market right now. GLP-1, GIP, amylin, and glucagon-based drugs all work by adding satiety signal. LEAP2 works by removing a hunger signal at its source.
That distinction has real human data behind it now, not just rodent work. A 2026 randomized, double-blind, placebo-controlled crossover study in men with obesity found that a multi-hour LEAP2 infusion reduced ad libitum food intake and attenuated the post-meal glucose spike, compared to placebo: a genuine human proof-of-concept for a target that is barely part of the mainstream peptide conversation.
Evidence reality
Early-stage human data exists (a controlled infusion study, not a long-term trial), but LEAP2 is not an approved obesity treatment, has no synthetic drug formulation on the market, and has no established research dosing protocol. The ghrelin/LEAP2 ratio itself is also being explored as a metabolic biomarker independent of any drug application: worth watching for that reason alone.
2. Elamipretide (SS-31): The Mitochondrial Peptide That Became Real Medicine
What it is
SS-31 (also known as elamipretide, MTP-131) is a small, cell-permeable tetrapeptide that concentrates in mitochondria and binds cardiolipin: the phospholipid that anchors the inner mitochondrial membrane’s structure and the electron transport chain.
What it’s being researched for
Mitochondrial disease, oxidative stress, heart failure, skeletal muscle bioenergetics, and, because mitochondrial membrane dysfunction is a proposed hallmark of aging, longevity biology more broadly.
Why it matters
SS-31 already has genuine standing in RUO circles as a mitochondrial-optimization compound (it appears in stack-building tools alongside MOTS-c and NAD+). What changes the picture is what happened outside that world: on September 19, 2025, the FDA granted accelerated approval to elamipretide HCl (brand name FORZINITY) as the first treatment for Barth syndrome, an ultra-rare mitochondrial disorder affecting roughly 150 people in the U.S. The approval is for improving muscle strength in patients 30 kg and up, built on knee-extensor strength data from the TAZPOWER trial, and it is explicitly conditional: continued approval depends on a confirmatory trial verifying clinical benefit.
That’s an important distinction from a full approval, but it’s still a real regulatory milestone: it’s described as the first approved mitochondria-targeted therapeutic of any kind, and it’s direct clinical validation that a short peptide can measurably improve mitochondrial bioenergetics in humans, not just in a dish or a mouse. Mechanistically, SS-31’s specificity (improving ATP production, reducing reactive oxygen species, and inhibiting formation of the mitochondrial permeability transition pore) is unusually well-characterized compared to the vague “antioxidant” framing applied to many longevity compounds.
Evidence reality
The strongest maturity profile of the five, an actual (accelerated) FDA approval, but that approval is disease-specific to Barth syndrome. It is not an approved treatment for aging, general mitochondrial “optimization,” or any indication outside its labeled use, and the approval itself remains contingent on confirmatory trial results.
3. KP1: The Klotho-Derived Anti-Fibrotic Peptide
What it is
KP1 (Klotho-derived peptide 1) is a 30-amino-acid fragment (residues Phe57–Gly86) of the KL1 domain of alpha-Klotho: the protein best known in longevity research as an anti-aging factor. Rather than requiring full recombinant Klotho, which is large and difficult to manufacture, KP1 isolates the specific functional piece responsible for one of Klotho’s effects.
What it’s being researched for
Kidney fibrosis, cellular senescence, TGF-β signaling, and, in follow-up work, liver fibrosis.
Why it matters
Fibrosis is one of biology’s least “marketable” but most consequential aging processes. It underlies progression in chronic kidney disease, heart failure, liver disease, and lung disease. In the original 2022 Nature Communications study out of the University of Pittsburgh, KP1 was shown to bind TGF-β receptor 2 directly, blocking the receptor’s downstream Smad2/3 and MAPK signaling. In mouse models of kidney injury (ischemia-reperfusion and ureteral obstruction), KP1 preserved kidney function, reduced fibrosis, and restored endogenous Klotho expression, outperforming ITD-1, a reference TGF-β receptor inhibitor, in both cell and animal experiments. A more recent follow-up study extended the same peptide to hepatic fibrosis driven by Klotho deficiency, suggesting the mechanism isn’t kidney-specific.
The design philosophy here is the more interesting story for peptide researchers generally: instead of chasing a vague “boost longevity protein levels” strategy, KP1 isolates one functional domain of a longevity protein and directs it at one well-defined, high-value mechanism. That’s a template other labs are likely to copy for other multi-domain longevity proteins.
Evidence reality
Preclinical: published, peer-reviewed rodent and cell-culture data across two organ systems, plus correlational human biopsy data, but no clinical trials and no established human dosing framework. KP1 isn’t currently sold as a standard RUO vial by mainstream peptide vendors.
4. 4L2-P13D: A Macrocyclic Antagonist Going After Fibrosis’s Newest Target
What it is
4L2-P13D is a laboratory-optimized macrocyclic peptide (a larger, ring-shaped peptide structure, distinct from the linear peptides most RUO discussions revolve around) engineered as a high-affinity antagonist of interleukin-11 (IL-11).
What it’s being researched for
IL-11 blockade, fibroblast activation, and renal fibrosis, with implications across kidney, heart, liver, and lung fibrosis given IL-11’s expanding role as a cross-organ pro-fibrotic cytokine.
Why it matters
IL-11 has gone from a minor cytokine to one of fibrosis research’s most closely watched targets in the space of a few years, because it appears to sit directly upstream of fibroblast activation across multiple organs: a single mechanism with relevance to several major disease categories at once. A 2025 Journal of Medicinal Chemistry paper describes the discovery and optimization of 4L2 into 4L2-P13D, reporting a binding affinity (KD) of 11 nM and an IC50 of 2.8 μM, with demonstrated renoprotective and antifibrotic effects in both cell-based and animal models.
Macrocyclic peptides like this one occupy a useful middle ground in drug design: they can often bind flat, featureless protein surfaces (the kind that defeat small molecules) with more oral/systemic tractability than a full antibody. As a discovery story, 4L2-P13D is also a preview of where a lot of next-generation peptide work is headed: purpose-built macrocycle libraries screened directly against a validated but historically “undruggable” target, rather than a peptide sequence borrowed from an existing biological source.
Evidence reality
Early-stage drug discovery: strong in vitro and in vivo preclinical data in a single 2025 publication, no clinical development reported. 4L2-P13D is sold in small quantities by specialty biochemical suppliers as a DMSO-soluble laboratory reagent for in vitro research; it is not a human-injectable product, has no reconstitution or dosing data of any kind, and there is no basis for treating it as one.
5. D13 and D41: What AI-Designed Peptide Drugs Actually Look Like
What they are
D13 and D41 are synthetic GLP-1 receptor agonist peptides that do not come from a natural template at all: they were generated by a deep-learning pipeline built to design entirely new peptide sequences from scratch (de novo design), rather than to modify an existing molecule like semaglutide.
What they’re being researched for
Obesity and type 2 diabetes, specifically the problem of extending a GLP-1 peptide’s half-life without losing potency.
Why it matters
The headline result isn’t really about D13 and D41 individually; it’s about the pipeline that produced them. Researchers reportedly generated 10,000 candidate GLP-1 receptor agonist sequences computationally, filtered that pool down to 60 that met stability, activity, and diversity criteria, and ran those 60 through real experimental validation (binding assays, surface plasmon resonance, and cAMP signaling assays), landing on a 62% in-vitro validation rate, notably high for a field where the gap between “designed on a computer” and “actually works in a test tube” is usually enormous.
Of the leads that emerged, D13 showed a half-life roughly 2.4× longer than semaglutide (about 19.9 hours vs. 8.2 hours) and produced weight loss in diet-induced obese mice statistically comparable to semaglutide over 21 days. D41 pushed half-life extension further, to roughly 2.8× semaglutide, with somewhat lower efficacy in the same model. Together they’re a concrete demonstration that an AI design pipeline can produce peptide leads competitive with an approved, blockbuster drug on core pharmacokinetic properties, not just plausible-looking sequences that fail on contact with a real assay.
Evidence reality
Early preclinical development: animal pharmacokinetics and efficacy data from a single 2025 study, no synthesis of either compound outside the originating research group as far as public sourcing shows, and no clinical trials. D13 and D41 are research leads, not compounds available for purchase from any research-chemical vendor.
The Pattern: Five Signals Pointing at Next-Decade Peptide Research
Read together, these five compounds aren’t a random grab-bag; they trace five distinct directions the field is moving in:
- Endogenous appetite brakes (LEAP2): treating the body’s own regulatory peptides as drug candidates, rather than only designing exogenous mimetics.
- Mitochondrial membrane repair (SS-31/elamipretide): direct pharmacological intervention on a specific organelle-level structure, now with regulatory validation in humans.
- Longevity-protein fragmentation (KP1): isolating one functional domain of a large, hard-to-manufacture longevity protein and directing it at a single mechanism.
- Fibrosis via macrocyclic antagonism (4L2-P13D): purpose-engineered peptide structures going after cytokine targets that have historically resisted small-molecule and antibody approaches.
- AI-native peptide design (D13/D41): generating and filtering thousands of candidate sequences computationally before a single one reaches a bench, compressing a process that used to take years of iterative synthesis.
Development-Stage Snapshot
Publication in a journal is not the same as clinical validation, and clinical validation for one indication is not the same as general availability. Here’s how the five actually stack up:
| Compound | Development maturity |
|---|---|
| Elamipretide / SS-31 | Highest maturity: FDA accelerated approval for Barth syndrome (September 2025), contingent on a confirmatory trial |
| LEAP2 | Early human proof-of-concept: controlled infusion study, no drug formulation or approval |
| KP1 | Preclinical / translational: peer-reviewed rodent and cell data across two organ systems |
| 4L2-P13D | Early drug discovery: single 2025 publication, in vitro/in vivo data, sold only as a lab reagent |
| D13 / D41 | AI-designed preclinical leads: one 2025 study, mouse pharmacokinetics and efficacy only |
That ordering matters more than any individual mechanism story. A compound with an accelerated FDA approval for a specific rare disease and a compound that exists only as a sequence in a supplementary data file are not comparable in any practical sense, even if both make for an interesting research writeup.
Why the “Loud” Peptides Aren’t Always the Ones That Matter Most
The peptides that dominate community discussion tend to be the ones with the most established supply chains and the most existing user-generated content, not necessarily the ones with the most interesting or best-validated mechanisms. LEAP2, KP1, 4L2-P13D, and D13/D41 barely register in that conversation (three of the four aren’t available as research-vial products at all), but each represents a research program tackling a genuine biological bottleneck with real mechanistic precision behind it. SS-31 shows where that kind of precision can eventually lead: an actual, if narrowly indicated, FDA approval.
The strongest angle in following peptide science isn’t tracking which compound has the loudest community marketing. It’s tracking which ones are solving real biological bottlenecks, and staying honest about exactly how far each one actually is from human use.
Frequently Asked Questions
Are LEAP2, KP1, 4L2-P13D, or D13/D41 available for purchase as research peptides?
As of this writing, 4L2-P13D is sold in small quantities by specialty biochemical suppliers as a DMSO-soluble in vitro laboratory reagent. LEAP2, KP1, and D13/D41 are not sold as standard research-vial products by mainstream peptide vendors: they exist primarily as published sequences and data in the scientific literature. SS-31/elamipretide is the only compound on this list with an established presence in the RUO peptide-vendor market.
Is elamipretide (SS-31) FDA-approved?
It has FDA accelerated approval, granted September 19, 2025 under the brand name FORZINITY, specifically to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Accelerated approval is conditional (continued approval depends on a confirmatory trial verifying clinical benefit), and the approval does not extend to any other indication.
What makes IL-11 an important fibrosis target?
IL-11 has emerged as a cytokine that sits close to the center of fibroblast activation across multiple organs, giving a single mechanism relevance to kidney, heart, liver, and lung fibrosis simultaneously: one reason it has drawn rapid drug-discovery interest, including macrocyclic peptide antagonists like 4L2-P13D.
Does an AI-designed peptide like D13 or D41 work differently in the body than a conventional peptide drug?
Not in terms of biology: D13 and D41 still act as GLP-1 receptor agonists through the same receptor semaglutide targets. What differs is how they were found: instead of modifying a known peptide, researchers generated thousands of candidate sequences computationally and screened them experimentally, which is a different discovery process, not a different mechanism of action.
Is any of this peptide research use only (RUO), and does that mean it’s safe or legal to use?
“Research use only” describes how a compound is sold and labeled, not whether it is approved, safe, or legal for human use. None of the compounds in this article have an established human dosing protocol, and RUO Codes does not provide dosing guidance for any compound. See the Peptide Laws by State page for how RUO status interacts with actual legal status.
Research Citations
- LEAP2 Reduces Ad Libitum Food Intake and Attenuates Postprandial Glucose Excursions in Men With Obesity. Diabetes, American Diabetes Association, 2026.
- LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity. Frontiers in Endocrinology, 2021.
- Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY (elamipretide HCl) for Barth Syndrome. PR Newswire, September 19, 2025.
- A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling. Nature Communications, 2022.
- Klotho-derived peptide 1 ameliorates hepatic fibrosis induced by αKlotho deficiency and liver injury. International Journal of Biological Sciences.
- De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy. Journal of Medicinal Chemistry, 68(19), 2025.
- AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists. Advanced Science, 2025.